Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 May;89(5):562–570. doi: 10.1111/j.1349-7006.1998.tb03298.x

Human Tumor Growth Suppression by Apoptosis Induced with Anti‐ErbB‐2 Chimeric Monoclonal Antibody

Shigeru Sasaki 1,✉, Masayuki Tsujisaki 1, Tsuneharu Jinnohara 1, Tadao Ishida 1, Masuo Sekiya 1, Masaaki Adachi 1, Shuji Takahashi 2, Yuji Hinoda 1, Kohzoh Imai 1
PMCID: PMC5921853  PMID: 9685861

Abstract

We established an anti‐ErbB‐2 mouse‐human chimeric monoclonal antibody (MoAb), CH401, which was able to kill cancer cells overexpressing the ErbB‐2 protein in vitro. The analysis of the killing mechanism indicated that MoAb CH401 might be the first anti‐ErbB‐2 mouse‐human chimeric MoAb which can induce the apoptosis of cancer cells, since morphological changes and DNA fragmentation were recognized in MoAb CH401‐treated cells. The ErbB‐2 receptor appears to have two opposing functions: acting as a receptor both for a growth factor and for an apoptotic factor. Our results indicate that MoAb CH401 treatment may prove to be very useful for cancer therapy.

Keywords: Key words, ErbB‐2, Apoptosis, G1 arrest, Chimeric monoclonal antibody, Growth factor receptor

Full Text

The Full Text of this article is available as a PDF (162.2 KB).

REFERENCES

  • 1. ) King , C. R. , Kraus , M. H. and Aaronson , S. A.Amplification of a novel v‐erbB‐related gene in a human mammary carcinoma . Science , 229 , 974 – 976 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Semba , K. , Kamata , N. , Toyoshima , K. and Yamamoto , T. Av‐erbB‐related protooncogene, c‐erbB‐2, is distinct from the c‐erbB‐1/epidermal growth factor‐receptor gene and is amplified in a human salivary gland adenocarcinoma . Proc. Natl. Acad. Sci. USA , 82 , 6497 – 6501 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. ) Yokota , J. , Yamamoto , T. , Toyoshima , K. , Terada , M. , Sugimura , T. , Battifora , H. and Cline , M. J.Amplification of c‐erbB‐2 oncogene in human adenocarcinomas in vivo . Lancet , I , 765 – 767 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Venter , D. J. , Tuzi , N. L. , Kumar , S. and Gullick , W. J.Overexpression of the c‐erbB‐2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification . Lancet , II , 69 – 72 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Slamon , D. J. , Godolphin , W. , Jones , L. A. , Holt , J. A. , Wong , S. G. , Keith , D. E. , Levin , W. J. , Stuart , S. G. , Udove , J. , Ullrich , A. and Press , M. F.Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer . Science , 244 , 707 – 712 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Yarden , Y.Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active . Proc. Natl. Acad. Sci. USA , 87 , 2565 – 2573 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Shepard , H. M. , Lewis , G. D. , Sarup , J. C. , Fendly , B. M. , Maneval , D. , Mordenti , J. , Figari , I. , Kotts , C. E. , Palladino , M. A. , Jr. , Ullrich , A. and Slamon , D.Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic . J. Clin. Immunol. , 11 , 117 – 127 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Harwerth , I.‐M. , Wels , W. , Schlegel , J. , Muller , M. and Hynes , N. E.Monoclonal antibodies directed to the erbB‐2 receptor inhibit in vivo tumor cell growth . Br. J. Cancer , 68 , 1140 – 1145 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Ishida , T. , Tsujisaki , M. , Hanzawa , Y. , Hirakawa , T. , Hinoda , Y. , Imai , K. and Yachi , A.Significance of erbB‐2 gene product as a target molecule for cancer therapy . Scand. J. Immunol. , 39 , 459 – 466 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Ishida , T. , Tsujisaki , M. , Hinoda , Y. , Imai , K. and Yachi , A.Establishment and characterization of mouse‐human chimeric monoclonal antibody to erbB‐2 product . Jpn. J. Cancer Res. , 85 , 172 – 178 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. ) Yamamura , M. , Hinoda , Y. , Sasaki , S. , Tsujisaki , M. , Oriuchi , N. , Endo , K. and Imai , K.A human/mouse chimeric monoclonal antibody against intercellular adhesion molecule‐1 for tumor radioimmunoimaging . Jpn. J. Cancer Res. , 87 , 405 – 411 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. ) Drebin , J. A. , Link , V. C. and Greene , M. I.Monoclonal antibodies specific for the neu oncogene product directly mediate anti‐tumor effects in vivo . Oncogene , 2 , 387 – 394 ( 1988. ). [PubMed] [Google Scholar]
  • 13. ) Hudziak , R. M. , Lewis , G. D. , Winget , M. , Fendly , B. M. , Shepard , H. M. and Ullrich , A.p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor . Mol. Cell Biol , 9 , 1165 – 1172 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. ) Lewis , G. D. , Figari , I. , Fendly , B. , Wong , W. L. , Carter , P. , Gorman , C. and Shepard , H. M.Differential responses of human tumor cell lines to anti‐p185HER2 monoclonal antibodies . Cancer Immunol. Immunother. , 37 , 255 – 263 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. ) Vitetta , E. S. and Uhr , J. W.Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy . Cancer Res. , 54 , 5301 – 5309 ( 1994. ). [PubMed] [Google Scholar]
  • 16. ) Drebin , J. A. , Link , V. C. , Weinberg , R. A. and Greene , M. I.Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene‐encoded tumor antigen . Proc. Natl. Acad. Sci. USA , 83 , 9129 – 9133 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Fendly , B. M. , Winget , M. , Hudziak , R. M. , Lipari , M. T. , Napier , M. A. and Ullrich , A.Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product . Cancer Res. , 50 , 1550 – 1558 ( 1990. ). [PubMed] [Google Scholar]
  • 18. ) Tagliabue , E. , Centis , F. , Campiglio , M. , Mastroianni , A. , Martignone , S. , Pellegrini , R. , Casalini , P. , Lanzi , C. , Menard , S. and Colnaghi , M. I.Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification . Int. J. Cancer , 47 , 933 – 937 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Bacus , S. S. , Stancovski , I. , Huberman , E. , Chin , D. , Hurwitz , E. , Mills , G. B. , Ullrich , A. , Sela , M. and Yarden , Y.Tumor‐inhibitory monoclonal antibodies to the HER‐2/neu receptor induce differentiation of human breast cancer cells . Cancer Res. , 52 , 2580 – 2589 ( 1992. ). [PubMed] [Google Scholar]
  • 20. ) Katsumata , M. , Okudaira , T. , Samanta , A. , Clark , D. P. , Drebin , J. A. , Jolicoeur , P. and Greene , M. I.Prevention of breast tumor development in vivo by downregulation of the p185neu receptor . Nat. Med. , 1 , 644 – 648 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Stancovski , I. , Hurwitz , E. , Leitner , O. , Ullrich , A. , Yarden , Y. and Sela , M.Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth . Proc. Natl. Acad. Sci. USA , 88 , 8691 – 8695 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. ) Hurwitz , E. , Stancovski , I. , Sela , M. and Yarden , Y.Suppression and promotion of tumor growth by monoclonal antibodies to ErbB‐2 differentially correlate with cellular uptake . Proc. Natl. Acad. Sci. USA , 92 , 3353 – 3357 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. ) Xu , F. , Lupu , R. , Rodriguez , G. C. , Whitaker , R. S. , Boente , M. P. , Berchuck , A. , Yu , Y. , Desombre , K. A. , Boyer , C. M. and Bast , R. C. , Jr.Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbB‐2 (HER‐2/neu) gene product p185 . Int. J. Cancer , 53 , 401 – 408 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Drebin , J. A. , Link , V. C. , Stern , D. F. , Weinberg , R. A. and Greene , M. I.Down‐modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies . Cell , 41 , 695 – 706 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Yonehara , S. , Ishii , A. and Yonehara , M.A cell‐killing monoclonal antibody (anti‐Fas) to a cell surface antigen co‐downregulated with the receptor of tumor necrosis factor . J. Exp. Med. , 169 , 1747 – 1756 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. ) Wu , X. , Fan , Z. , Masui , H. , Rosen , N. and Mendesohn , J.Apoptosis induced by anti‐epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin . J. Clin. Invest. , 95 , 1897 – 1905 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES